Sutro Biopharma (STRO) Net Cash Flow (2017 - 2025)

Sutro Biopharma (STRO) has 9 years of Net Cash Flow data on file, last reported at -$7.8 million in Q4 2025.

• For the quarter ending Q4 2025, Net Cash Flow fell 149.58% year-over-year to -$7.8 million; the trailing twelve-month figure through Dec 2025 stood at -$132.2 million (down 209.21% YoY), and the FY2025 full-year result was -$132.2 million, down 209.21% from the prior year.
• Net Cash Flow fell to -$7.8 million in Q4 2025, from $1.9 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $172.6 million in Q2 2023 to a low of -$153.3 million in Q3 2023.
• A 5-year average of -$7.4 million and a median of -$903000.0 in 2021 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow tumbled 21127.27% in 2021 and soared 8648.08% in 2022, its largest moves.
• Tracing STRO's Net Cash Flow over 5 years: stood at -$293000.0 in 2021, then tumbled by 16802.73% to -$49.5 million in 2022, then soared by 74.63% to -$12.6 million in 2023, then surged by 225.15% to $15.7 million in 2024, then tumbled by 149.58% to -$7.8 million in 2025.
• Business Quant data shows STRO's Net Cash Flow at -$7.8 million in Q4 2025, $1.9 million in Q3 2025, and -$42.2 million in Q2 2025.